Post-doctoral Fellow Dr Alba Rodriguez-Meira from the Mead Group has received a 2021 ASH Abstract Achievement Award and will deliver a plenary session at the 63rd American Society of Hematology Annual Meeting and Exposition.
The session, titled ‘Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN’ will be held on Sunday 12th December 2021.
The abstract applies the TARGET-seq platform developed in the Mead Group in order to dissect disease mechanisms in leukemic transformation affecting patients with chronic myeloid malignancies. The work focuses in particular on the impact of TP53 mutations –the most common mutation occurring in all cancer types.
'I am extremely grateful to the ASH Committee for selecting me for the Outstanding Abstract Achievement Award, which will allow me to attend ASH 2021 in person in Atlanta' says Dr Rodriguez-Meira. 'I am really excited to present our work on the evolution of TP53-mutant myeloid neoplasms, in what will be my first in person conference in the last two years! Attending ASH will allow me to establish key interactions and collaborations to better understand the molecular mechanisms underlying this extremely poor prognosis disease and how we might be able to target it.'
Many Congratulations to Dr Rodriguez-Meira and the Mead Group!
The 63rd ASH Annual Meeting and Exposition is running from December 11th-14th 2021 both in person in Atlanta, Georgia, and virtually.
For more details on the session please visit the ASH website